Innovent Biopharmaceuticals

Innovent Biopharmaceuticals is a leading global biopharmaceutical company dedicated to developing, manufacturing, and commercializing high-quality innovative medicines for the treatment of major diseases. Founded in 2011 and headquartered in Suzhou, China, the company has built a fully integrated platform encompassing R&D, CMC, and commercialization. Its extensive pipeline includes over 30 assets across oncology, metabolic, autoimmune, and ophthalmology therapeutic areas, with several products already successfully commercialized, including the PD-1 inhibitor Tyvyt. Innovent is recognized for its strategic global partnerships with industry leaders such as Eli Lilly and Sanofi, aimed at expanding the reach of its innovative therapies. The company maintains large-scale GMP-compliant manufacturing facilities to ensure the production of affordable, high-quality biologics for patients worldwide.